Iodixanol development

The incidence of late adverse reactions to the iso-osmo-lar agent iodixanol has also been investigated in a retrospective comparison with the non-ionic monomer iohexol. Reactions after 3075 injections were reviewed. Patients were sent a written questionnaire to find out about the incidence of any acute or delayed reactions. Those who developed reactions were interviewed by telephone and specific second questionnaires were administered. The incidence of adverse reactions was low (2% for late adverse reactions and 2.3% for acute reactions). There was no significant difference in the incidence of acute or delayed adverse reactions to iohexol and iodixanol and there were no serious reactions (32). 

A 54-year-old woman and a 68-year-old man developed rashes 24 hours after intravascular injection of iohexol (a non-ionic monomer) (205). The woman developed widespread pruritic erythema and eyelid edema. The man developed a maculopapular rash involving the trunk and legs. Both patients were treated with antihistamines, which resulted in complete recovery within 1 week. The man had slight desquamation of the affected area after his rash resolved. Patch tests were positive to iohexol in both patients. The man also had a positive patch test to iodixanol and the woman was positive to the non-ionic monomer ioversol. 

Acute thyrotoxicosis (TTX) developed several days following a coronary angioplasty procedure necessitating 260 ml of iodixanol (320 mg/ml iodine-containing contrast media) in a 72-year-old age male with cardiovascular disease and prior thyroid toxic nodular goitre. Euthyroid status was established with carbimazole treatment [19A]. 

---